Current Duke Appointments & Affiliations
Professor of Medicine
·
2024 - Present
Medicine, Infectious Diseases,
Medicine
Membership in the Duke Clinical Research Institute
·
2015 - Present
Duke Clinical Research Institute,
Institutes and Centers
Recent Scholarly Works
Escherichia coli ST131 Drives Carbapenem Use for E. coli Bloodstream Infections.
Journal article Clin Infect Dis · July 23, 2026 BACKGROUND: Ceftriaxone-resistant Escherichia coli infections are increasingly common, partially because of the emergence of E. coli sequence type 131 (ST131), including its subclade C2/H30Rx, which produce extended-spectrum β-lactamases. METHODS: A prospe ... Full text Link to item CiteCeftobiprole and the kidney: secondary analyses of the ERADICATE Staphylococcus aureus bacteraemia trial
Journal article Cmi Communications · July 1, 2026 Objectives Ceftobiprole demonstrated noninferiority to daptomycin for the treatment of Staphylococcus aureus bacteraemia. A range of post hoc exploratory analyses were undertaken to better inform additional key clinical questions—including how ceftobiprole ... Full text CiteEarly Combination Therapy for MRSA Bacteremia: Double Coverage or Double Trouble?
Journal article Clin Infect Dis · June 9, 2026 Full text Link to item CiteRecent Grants
A PHASE 3 EFFICACY AND SAFETY STUDY OF FOSMANOGEPIX FOR THE TREATMENT OF ADULT PARTICIPANTS WITH CANDIDEMIA AND/OR INVASIVE CANDIDIASIS
ResearchInvestigator · Awarded by Basilea Pharmaceutica International Ltd, Allschwil · 2025 - 2028Invasive Candidiasis
Clinical TrialPrincipal Investigator · Awarded by Basilea Pharmaceutica · 2024 - 2028Antibacterial Resistance Leadership Group (ARLG)
ResearchCo Investigator · Awarded by National Institute of Allergy and Infectious Diseases · 2013 - 2026View All Grants
Education
Wake Forest University ·
2005
M.D.